3 ms·

Can someone explain why it's taken so long to go from the success CAR-T had with non solid tumors, to getting an immunotherapy that indeed is effective against

• adamredwoods 2y ago
  "Success" for CAR-T is hazy, as many participants died from unrealized side effects, including new cancers. >> The FDA indicated that patients and participants in clinical trials receiving CAR T-cell therapy should be monitored life-long for secondary malignancies. https://www.onclive.com/view/fda-requires-boxed-warning-for-risk-of-t-cell-malignancies-with-approved-car-t-cell-therapies https://www.onclive.com/view/fda-requires-boxed-warning-for-... Regarding solid tumors, I've only hear about T-cell exhaustion, but CAR-T solid tumor trials are ongoing: https://med.stanford.edu/cancer/about/news/car-t-solid-tumor.html https://med.stanford.edu/cancer/about/news/car-t-solid-tumor... >> Although CAR T-cells directed toward the HER2-expressing tumors have been extensively studied in clinical trials, safety concerns have emerged following the death of a CRC patient who received 1×1010 third-generation HER2-CAR T-cells. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067596/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067596/